Factors Affecting Medication Adherence to Topical Acne Medications: a Single-center, Prospective Study Evaluating the Adherence and Patient Satisfaction to Single and Multiple Topical Acne Medications

Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects including treatment failure, increased healthcare costs, and decreased quality of life. Primary nonadherence refers to problems acquiring and starting treatment. Challenges to this form of nonadherence include a lack of knowledge, misunderstanding of usage, poor communication with provider, increased cost, and fear of side effects.2 Secondary nonadherence refers to when the patient does not use the medication as prescribed. Hurdles to secondary nonadherence include delayed results, increased complexity of treatment plan, adverse effects, busy lifestyle, and inconvenience.2

开始日期2024-02-15

申办/合作机构

Wake Forest School of Medicine

[+1]

EUCTR2018-004338-13-NL / Unknown status临床4期IIT

Short term clinical efficacy of topical treatment with clindamycin-benzoyl peroxide gel compared with clindamycin lotion in mild to moderate Hidradenitis Suppurativa - TOPIC

开始日期2019-06-11

申办/合作机构-

NCT03257202 / Completed临床2期IIT

Cutibacterium Acnes Persists Despite Topical Clindamycin and Benzoyl Peroxide

This study is about preventing surgical site infections of the shoulder. We hope to learn if clindamycin alone, benzoyl peroxide alone, or clindamycin and benzoyl peroxide together can affect growth of Propionibacterium acnes in the dermal layer.

开始日期2017-09-11

申办/合作机构

University of Southern California

100 项与克林霉素磷酸酯/过氧苯甲酰相关的临床结果

登录后查看更多信息

100 项与克林霉素磷酸酯/过氧苯甲酰相关的转化医学

登录后查看更多信息

100 项与克林霉素磷酸酯/过氧苯甲酰相关的专利（医药）

登录后查看更多信息

247

项与克林霉素磷酸酯/过氧苯甲酰相关的文献（医药）

2024-03-22·Biomedical Research

Indoxyl sulfate contributes to colorectal cancer cell proliferation and increased EGFR expression by activating AhR and Akt

Article

作者: Yano, Shozo ; Ichisaka, Yu ; Nishimura, Kohji ; Niwa, Toshimitsu ; Shimizu, Hidehisa

Although patients with chronic kidney disease (CKD) have a higher risk of colorectal cancer (CRC) aggravation, the connection between these two diseases is not well understood. Recent studies have shown that both CKD and CRC aggravation are closely related to an increased abundance of indole-producing Fusobacterium nucleatum in the gut. The indole absorbed from the gut is eventually metabolized to indoxyl sulfate in the liver. Since indoxyl sulfate is involved not only in accelerating CKD progression but also in the initiation and development of its associated complications, the present study aimed to clarify whether indoxyl sulfate induces the proliferation of CRC cells. This study found that indoxyl sulfate induced the proliferation of CRC-derived HCT-116 cells by activating the aryl hydrocarbon receptor (AhR) and the proto-oncogene Akt. The AhR antagonist CH223191 and Akt inhibitor MK2206 suppressed indoxyl sulfate-induced proliferation of HCT-116 cells. We also found that indoxyl sulfate upregulated epidermal growth factor receptor (EGFR) expression, which is associated with poor prognosis of CRC, whereas CH223191 and MK2206 repressed EGFR expression. Furthermore, indoxyl sulfate increased the sensitivity of CRC cells to EGF by upregulating EGFR expression. These findings suggest that indoxyl sulfate may be an important link between CKD and CRC aggravation.

2024-01-01·Neuroscience Letters

Effects of the uremic toxin indoxyl sulfate on seizure activity, learning and brain oxidative stress parameters in mice

Article

作者: Raszewski, Grzegorz ; Łukawski, Krzysztof ; Czuczwar, Stanisław J

Patients with end-stage renal disease often have neurological disorders, with a higher incidence of memory impairment or epilepsy than in the general population. Patients undergoing hemodialysis are particularly exposed to the biological effects of uremic toxins. Indoxyl sulfate (IS) is one of the most potent uremic toxins; however, its possible effects on seizure susceptibility or memory functions have yet to be elucidated. In the current study, we focused on investigating the possible convulsant and amnesic effects of IS in recognized animal models. The study was performed on adult male Swiss mice. IS and scopolamine (SCO) were administered intraperitoneally (i.p.), and pentylenetetrazole (PTZ) was injected subcutaneously (s.c.). All substances were given as single injections. Acute IS administration (400 mg/kg) led to its accumulation in the brain. IS at doses of 200 and 400 mg/kg decreased the PTZ convulsive threshold, and at the same doses, it did not significantly affect the threshold for electroconvulsions. IS (200 and 400 mg/kg) did not impair learning in the passive avoidance test and did not increase the SCO-induced memory impairment in this test. IS increased lipid peroxidation, decreased the level of reduced glutathione, and reduced the activity of superoxide dismutase and catalase in mouse brains. Exposure to IS did not significantly change the activity of acetylcholinesterase in the brain tissue. This study shows that acute exposure to IS induces oxidative stress in the brain and potentiates PTZ-induced seizures in mice. Further studies are needed to find out whether IS-induced oxidative stress may affect epileptic seizures and/or epileptogenesis.

2023-12-20·Nephrology Dialysis Transplantation

Indoxyl sulfate inhibits muscle cell differentiation via Myf6/MRF4 and MYH2 downregulation

Article

作者: McKay, Nathalie ; Beau, Alice ; Burtey, Stéphane ; Bartoli, Marc ; Dou, Laetitia ; Chermiti, Rania ; Bataille, Stanislas ; Aniort, Julien ; Da Silva, Nathalie ; Poitevin, Stéphane ; Koppe, Laetitia ; Benoit, Bérengère

ABSTRACTBackgroundChronic kidney disease (CKD) is associated with a significant decrease in muscle strength and mass, possibly related to muscle cell damage by uremic toxins. Here, we studied in vitro and in vivo the effect of indoxyl sulfate (IS), an indolic uremic toxin, on myoblast proliferation, differentiation and expression of myogenic regulatory factors (MRF)—myoblast determination protein 1 (MyoD1), myogenin (Myog), Myogenic Factor 5 (Myf5) and myogenic regulatory factor 4 (Myf6/MRF4)—and expression of myosin heavy chain, Myh2.MethodsC2C12 myoblasts were cultured in vitro and differentiated in myotubes for 7 days in the presence of IS at a uremic concentration of 200 µM. Myocytes morphology and differentiation was analyzed after hematoxylin-eosin staining. MRF genes’ expression was studied using reverse transcription polymerase chain reaction in myocytes and 5/6th nephrectomized mice muscle. Myf6/MRF4 protein expression was studied using enzyme-linked immunosorbent assay; MYH2 protein expression was studied using western blotting. The role of Aryl Hydrocarbon Receptor (AHR)—the cell receptor of IS—was studied by adding an AHR inhibitor into the cell culture milieu.ResultsIn the presence of IS, the myotubes obtained were narrower and had fewer nuclei than control myotubes. The presence of IS during differentiation did not modify the gene expression of the MRFs Myf5, MyoD1 and Myog, but induced a decrease in expression of Myf6/MRF4 and MYH2 at the mRNA and the protein level. AHR inhibition by CH223191 did not reverse the decrease in Myf6/MRF4 mRNA expression induced by IS, which rules out the implication of the ARH genomic pathway. In 5/6th nephrectomized mice, the Myf6/MRF4 gene was down-regulated in striated muscles.ConclusionIn conclusion, IS inhibits Myf6/MRF4 and MYH2 expression during differentiation of muscle cells, which could lead to a defect in myotube structure. Through these new mechanisms, IS could participate in muscle atrophy observed in CKD.

项与克林霉素磷酸酯/过氧苯甲酰相关的新闻（医药）

2024-07-16

·drugs

'Staying Regular' Is Good for Good Health

TUESDAY, July 16, 2024 -- Being regular is good for you, a new study shows. Predictable bowel movements could be tied to your long-term health, allowing your body to absorb essential nutrients without producing harmful organ-damaging toxins, researchers found. The “Goldilocks zone” of bowel movement frequency, once or twice a day, is associated with better health, results show. That gives gut microbes enough time to digest dietary fiber, which they ferment into beneficial short-chain fatty acids, explained lead researcher Johannes Johnson-Martinez , a doctoral student with the Institute for Systems Biology in Seattle. “After that, the ecosystem switches to fermentation of proteins, which produces several toxins that can make their way into the bloodstream,” Johnson-Martinez explained in an institute news release. For the study, researchers analyzed medical and lifestyle data for more than 1,400 healthy adults, according to the study published July 16 in the journal Cell Reports Medicine. These folks were divided into four groups based on bowel movement frequency -- constipation , low-normal, high-normal and diarrhea . The constipated moved their bowels once or twice a week, low-normal three to six times a week, and high-normal one to three times a day. People with constipation and diarrhea tend to have higher levels of bacteria associated with toxic protein fermentation, results showed. The toxins produced by protein fermentation can cause organ damage, the researchers added. For example, a protein fermentation byproduct called indoxyl-sulfate is significantly associated with reduced kidney function, results show. Blood levels of that byproduct and another toxin called p-cresol-sulfate were elevated in people with constipation. Meanwhile, other toxins associated with liver damage were higher in people with diarrhea. “Chronic constipation has been associated with neurodegenerative disorders and with chronic kidney disease progression in patients with active disease,” said researcher Sean Gibbons , an associate professor with the Institute for Systems Biology. “However, it has been unclear whether or not bowel movement abnormalities are early drivers of chronic disease and organ damage, or whether these retrospective associations in sick patients are merely a coincidence,” Gibbons added. “Here, in a generally healthy population, we show that constipation, in particular, is associated with blood levels of microbially derived toxins known to cause organ damage, prior to any disease diagnosis.” Not surprisingly, people tend to be in the Goldilocks zone if they eat a fiber-rich diet, drink lots of water, and have regular exercise, researchers said. Younger people, women and those with a lower BMI tend to have less frequent bowel movements, results show. Mental health also can affect a person’s bowel movements, results show. “Overall, this study shows how bowel movement frequency can influence all body systems, and how aberrant bowel movement frequency may be an important risk factor in the development of chronic diseases,” Gibbons said. “These insights could inform strategies for managing bowel movement frequency, even in healthy populations, to optimize health and wellness.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2022-09-13

·BioSpace

Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera’s Head of Sales & Marketing, and will help execute the Company’s U.S. sales division and objectives including the strategic design, expansion and leadership of its sales team. He will oversee recruiting and staffing to support Ameluz®, BF-RhodoLED® and Xepi® commercial efforts, as well as spearhead planning for the launch of BF-RhodoLED XL®. Mr. DiGirolamo brings to Biofrontera more than 25 years of experience in building pharmaceutical sales and commercial teams with a particular expertise in dermatology. Most recently he served as Vice President of Sales at Verrica Pharmaceuticals, a medical dermatology company where he built their U.S. sales infrastructure in preparation for a commercial launch of its drug-device combination product for the treatment of molluscum contagiosum. This provides valuable experience for working with Biofrontera’s combination of Ameluz® and the RhodoLED® lamps. “Gerard’s insight and understanding of the dermatology market, along with the many relationships he’s cultivated within our industry will be extremely valuable in working with Mark Baldyga on the successful implementation of our commercial strategy. His approach involving collaborating with medical affairs, marketing, key opinion leaders and national influencers through advisory boards and conferences fully aligns with our mission. He is passionate about building cohesive and collaborative teams that have led to successful product launches and market-share gains. We are delighted to have Gerard lead our commercial team and welcome him to Biofrontera,” stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. “I’m proud to join Biofrontera and to support their commitment to dermatological innovation. With my experience in building and supporting teams at national and regional levels, I look forward to leveraging my networks to position Ameluz-PDT as the first-choice treatment for actinic keratosis and establishing the optimal commercial infrastructure for a successful launch of BF-RhodoLED XL®,” stated Mr. DiGirolamo. Prior to Verrica Pharmaceuticals, Mr. DiGirolamo was a Field Vice President at GlaxoSmithKline (GSK) and previously spent 16 years with Stiefel, now part of GSK. At GSK he worked with multiple dermatology brands and exceeded sales forecasts including for the launch of Fabior Foam®, a treatment for psoriasis and acne. As Executive National Account Manager at Stiefel he led negotiations with national managed care organizations, securing unrestricted access to the acne therapy Duac CS™ and coverage of the seborrheic dermatitis therapies Extina™ and Xologel™. Prior to Stiefel, he was an Area and District Sales Manager at Novartis. Mr. DiGirolamo holds a B.A. from Rutgers University. About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit . Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company’s business and marketing strategy, future operations and business, potential to expand the label of Ameluz®, market presence and position of Ameluz® and ongoing clinical trials conducted by our licensing partners and the future impact of such trials on the market for Ameluz®. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to complete the transition to a public company; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at . Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contacts: Biofrontera Inc. Anke zur Mühlen +1 781 486 1539 us-ir@biofrontera.com LHA Investor Relations Tirth T. Patel +1 212 201 6614 tpatel@lhai.com # # #

2022-09-09

·药时代

免疫调节的魔术多面手——AHR

芳香烃受体（Aryl Hydrocarbon Receptor, AHR）是一种在细胞内可以结合配体的转录调控因子。正常情况下，AHR存在于细胞质中，与多种伴侣蛋白形成复合物。但AHR在与配体结合后，会通过核孔进入细胞核内并与芳香烃受体核转位因子（Aryl Hydrocarbon Receptor Nuclear Translocator, ARNT）形成二聚体。形成的二聚体可以与DNA中的异源响应元件（Xenobiotic response element，XRE）结合，促进下游基因表达。AHR在核内同时也能与其他转录因子结合，从而影响受到结合的转录因子调控的基因的表达。在AHR信号通路调控的蛋白中，细胞色素P450超家族（cytochrome P450）是研究得最透彻的。AHR的激活可以直接引发CYP1A1、CYP1A2等蛋白的表达，而这些酶对芳香族化合物的代谢起着至关重要的作用：不仅负责外源性毒性物质的代谢，也会影响多种药物的生物代谢。不仅如此，近来研究还发现，AHR信号通路对维持免疫系统平衡有着重要的意义。1外源AHR激动剂最早发现的AHR配体属于多环芳烃化合物（polycyclic aromatic hydrocarbons）及其衍生物，其中四氯二苯并-p-二恶英（2,3,7,8-tetracholrodibenzo-p-dioxin, TCDD）是目前效价最强的AHR激动剂之一。这类物质一般来源于生物体外部，长期摄入会造成毒性反应，带来组织损伤且具有高度致癌性。然而在小鼠的急性移植物抗宿主病（acute graft-vs-host disease）模型中，短期TCDD处理能够产生具有免疫抑制能力的类Treg细胞亚群，这个现象是依赖于AHR的表达。在小鼠感染流感病毒的模型中，TCDD处理激活AHR通路后降低了具有细胞杀伤功能的CD8+ T细胞反应，导致CD8+ T细胞的表观遗传学谱与基因表达谱发生类似耗竭CD8+ T细胞的变化。在一个小鼠系统性红斑狼疮的模型中，TCDD处理降低了白蛋白尿、血清中抗DNA抗体及总IgG抗体浓度，整体减轻了自身免疫症状并降低了死亡率。2内源AHR激动剂除了外源激动剂外，研究人员还发现AHR有许多内源性激动剂。其中，必需氨基酸之一的色氨酸可以通过吲哚胺2,3-双加氧酶（indoleamine 2,3-dioxygenase，IDO）以及色氨酸2,3-双加氧酶（tryptophan 2,3-dioxygenase，TDO）生成犬尿氨酸（kynurenine），犬尿氨酸本身就有一定的AHR激动剂活性，同时犬尿氨酸还会进一步代谢成犬尿喹啉酸（kynurenic acid）、黄尿酸（xanthurenic acid）等具有更强效价的AHR激动剂。另外，色氨酸还可以通过氧化反应生成效价非常强的AHR激动剂ITE（2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid methyl ester），或者通过UV光照生成FICZ（6-formylindolo[3,2-b]carbazole）。从白塞氏综合征（Behçet’s disease）病人血液中搜集的单核来源树突状细胞经过ITE或FICZ处理后会下调共刺激分子表达，降低脂多糖引发的炎症因子（如IL-6，TNF-a等）的分泌。然而在小鼠的实验性变态反应性脑脊髓炎（experimental autoimmune encephalomyelitis，EAE）模型中，FICZ处理激活AHR后导致了分泌白介素22的TH17细胞的增殖以及白介素22分泌的增加，最终加重了病变。有趣的是，在EAE模型中，TCDD的处理会激活Treg细胞的免疫抑制作用，从而对病变起到保护性作用。这说明不同AHR激动剂在特定条件下可能体现出不同的生物学反应，增加了研究的复杂性，但同时也扩展了AHR信号通路免疫调节的可能性。3其他来源AHR激动剂生物体内还有一个重要的AHR激动剂来源：共生菌群。大肠杆菌（Escherichia coli）产生的色氨酸酶（tryptophanase）可以将食物来源的色氨酸分解成吲哚类物质，然后在肝内被转化成AHR的激动剂硫酸-3-吲哚酚（indoxyl-3-sulfate, I3S）。而滋养节杆菌（Arthrobacter pascens）、梭状芽孢杆菌（Clostridium sporogenes）及罗伊氏乳杆菌（Lactobacillus reuteri）等可以将色氨酸转化成吲哚-3-乙酸（indole-3-acetic acid, IAA）、吲哚-3-甲醛（indole-3- aldehyde, I3A）等AHR激动剂。肠道内菌群产生的I3A能够通过激活AHR使肠内黏膜3型先天淋巴样细胞（type 3 innate lymphoid cells）分泌白介素22，维持肠内菌群平衡。除此之外，食物尤其是十字花科植物来源的硫代葡萄糖苷（glucosinolates）会水解成吲哚-3-甲醇（indole-3-carbinol, I3C）及吲哚并[3,2-b]咔唑（indolo[3,4-b] carbazole, ICZ）等AHR激动剂。这些激动剂对AHR信号通路的激活对维持小肠上皮内淋巴细胞（intraepithelial lymphocytes, IELs）的稳定有着重要作用，从而维持上皮细胞的增殖，控制炎症反应。在硫酸葡聚糖钠盐（dextran-sodium-sulfate）引发的结肠炎模型中，食物来源激动剂对AHR的激活可以减轻炎症，降低病变严重程度。表1 部分开发中的AHR激动剂免疫调节类药物4结语AHR作为细胞感知外界环境的一个感受器，在屏障细胞及部分免疫细胞中都有高表达，而AHR信号通路在免疫系统调节过程中也被证明是一个关键的信号通路。AHR激动剂已经在一些代表性的自身免疫疾病模型中（包括系统性红斑狼疮、白塞氏综合征、多样性硬化、炎性肠病等）显示出作用。同时由于AHR激动剂的多样性以及不同激动剂产生的不同效应，为靶向激活AHR信号通路的药物设计带来更多的可能性。Dermavant Sciences公司针对银屑病的药物tapinarof已经被FDA批准上市。Azora Therapeutics公司针对溃疡性结肠炎的药物ATI-177以及针对化脓性汗腺炎与银屑病的药物AT-193已经进入临床I期，Resolvex Pharmaceuticals公司针对特异性皮炎和银屑病的药物RLV-102也处于临床前的阶段。我们期待未来可以有更多靶向AHR的免疫调节类药物成功问世。参考资料[1] Shinde, R. & McGaha, T. L. The Aryl Hydrocarbon Receptor: Connecting Immunity to the Microenvironment. Trends. Immnunol. 39:1005-1020. 2018.[2] Quintana, F. J. et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature. 453:65-71. 2008.[3] Schiering, C. et al. Feedback control of AHR signaling regulates intestinal immunity. Nature. 542:242-245. 2017.[4] Li, Y. et al. Exogeneous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 147:629-640. 2011.封面图来源：123rf版权声明/免责声明本文为授权转载文章，版权归拥有者。仅供感兴趣的个人谨慎参考，非商用，非医用、非投资用。欢迎朋友们批评指正！衷心感谢！文中图片、视频为授权正版作品，或来自微信公共图片库，或取自公司官网/网络根据CC0协议使用，版权归拥有者。任何问题，请与我们联系（电话：13651980212。微信：27674131。邮箱：contact@drugtimes.cn）。衷心感谢！推荐阅读突发！创始人只得59分！这份药味十足的「药时代高考」模拟卷，究竟有多硬核？HER2 ADC终结者？！「DS-8201」断送了多少新药的“锦绣前程”？三院士齐聚，150多位专家出席！2022上海国际生物医药产业周系列活动——上海源创新药高峰论坛即将启幕首次亮相世界人工智能大会，晶泰科技「自动化实验室」，自主研发突破时空瓶颈新药版「叶公好龙」和新概念「龙线」全网首发！~~谁是中国制药江湖的「孤勇者」？| 欢迎为30家企业投票！创新论英雄，2022年勃林格殷格翰创新大赛，为只缺“伯乐”的你而来！嘉和生物发布2022年度中期业绩报告腾盛博药宣布中国管理团队调整重磅喜讯！默沙东九价HPV疫苗获批适用于9至45岁适龄女性接种点击这里，报名参加第三届中国新药CMC高峰论坛！

AHA会议创新药疫苗抗体抗体药物偶联物

100 项与克林霉素磷酸酯/过氧苯甲酰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	D10AE51	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脓疱性痤疮	澳大利亚	Glaxosmithkline Australia Pty Ltd.	2006-01-30
寻常痤疮	美国	Bausch Health Americas, Inc.	2000-12-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常痤疮	临床前	加拿大	Dow Pharmaceutical Sciences, Inc.	2006-10-01
寻常痤疮	临床前	伯利兹	Dow Pharmaceutical Sciences, Inc.	2006-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01796665 (CTgov)	临床3期	寻常痤疮	1,180	Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% (Test Product)	壓網窪鬱構願觸顧廠鑰(餘鹹選獵獵艱願顧築願) = 廠鹽製製鬱願願壓鏇範製醖製觸鏇鏇糧網網築 (觸鏇襯鏇餘壓夢艱廠鏇, 鹽選淵選衊壓襯糧糧鹽 ~ 艱獵鹹遞網遞鏇積鏇憲) 更多	-	2021-01-20
				Acanya Gel (Reference Product)	壓網窪鬱構願觸顧廠鑰(餘鹹選獵獵艱願顧築願) = 淵淵築獵製觸醖餘觸餘製醖製觸鏇鏇糧網網築 (觸鏇襯鏇餘壓夢艱廠鏇, 餘鹹繭齋鹹壓蓋齋積淵 ~ 獵網積顧鑰願製構觸夢) 更多
NCT03122457 (CTgov)	临床2期	光化性角化病	22	lidamycin phosphate+benzoyl peroxide 1.2%/3.75% combination	製獵憲醖構壓廠選糧醖(糧衊築淵艱窪構醖憲顧) = 窪齋夢醖構顧鏇窪蓋餘鬱齋廠選鏇網鹽繭顧顧 (鑰製鏇蓋膚膚獵膚鑰積, 構鹽醖製顧蓋顧糧鏇獵 ~ 範醖築鹽衊築餘顧餘糧) 更多	-	2020-09-04
NCT01237821 (CTgov)	N/A	寻常痤疮	66	Effaclar (Effaclar)	鹹齋窪製鹽齋觸壓築窪(鹹鏇範觸膚窪窪遞糧願) = 蓋蓋壓繭窪鬱選襯範齋餘膚鏇鑰獵淵襯壓觸遞 (鏇憲艱簾願襯鬱鬱鏇餘, 憲憲餘鹽餘願膚顧憲醖 ~ 顧繭繭淵鹹遞獵壓艱簾) 更多	-	2019-07-16
				BenzaClin (Benzaclin)	鹹齋窪製鹽齋觸壓築窪(鹹鏇範觸膚窪窪遞糧願) = 糧醖觸遞遞夢範襯積廠餘膚鏇鑰獵淵襯壓觸遞 (鏇憲艱簾願襯鬱鬱鏇餘, 製鑰醖廠壓廠糧壓餘憲 ~ 鬱鹽窪壓窪糧艱鑰夢鏇) 更多
NCT03402893 (CTgov)	临床4期	色素沉着过多 \| 寻常痤疮	21	ONEXTON Topical Gel	積壓餘鬱淵齋鏇築襯糧(艱膚觸醖構願積夢鹹構) = 願獵廠醖網遞淵襯網淵觸壓壓願齋襯積範鏇餘 (餘鬱顧製鹹糧積糧獵積, 獵蓋廠淵製壓壓網範顧 ~ 顧廠鬱網獵餘齋齋遞憲) 更多	-	2019-02-19
NCT01445301 (115287, CTgov)	临床3期	寻常痤疮	800	GSK2585823 (GSK2585823 Once Daily)	糧壓簾窪膚鹽鏇積網築(廠構製鏇膚糧鬱夢蓋壓) = 獵遞壓鑰遞鏇餘艱繭築襯繭積鬱築窪製鏇夢鹹 (顧築鏇艱網憲獵醖鬱襯, 膚齋鹹窪壓壓網憲選鹹 ~ 壓觸獵範製觸願築齋積) 更多	-	2018-04-27
				GSK2585823 (GSK2585823 Twice Daily)	糧壓簾窪膚鹽鏇積網築(廠構製鏇膚糧鬱夢蓋壓) = 網餘顧糧鹹簾衊膚壓範襯繭積鬱築窪製鏇夢鹹 (顧築鏇艱網憲獵醖鬱襯, 觸壓膚鹹遞齋糧鏇遞鹹 ~ 網願壓艱積窪網齋艱獵) 更多
NCT02058628 (CTgov)	临床4期	寻常痤疮	222	DUAC (DUAC®)	艱醖糧築繭膚蓋選艱鬱(憲窪築憲艱築簾餘構鬱) = 遞鏇鏇網鏇壓壓積憲構壓獵夢顧繭襯繭壓鬱蓋 (憲築齋憲蓋觸顧糧積鏇, 構襯繭窪鹽鏇齋淵鹽膚 ~ 醖築鑰憲選願構築窪選) 更多	-	2017-08-25
				SKINOREN (SKINOREN®)	艱醖糧築繭膚蓋選艱鬱(憲窪築憲艱築簾餘構鬱) = 願顧網選窪糧壓齋簾鬱壓獵夢顧繭襯繭壓鬱蓋 (憲築齋憲蓋觸顧糧積鏇, 鏇鹽夢積簾衊積構獵糧 ~ 壓製網齋鬱憲廠鏇窪艱) 更多
NCT00671749 (CTgov)	临床4期	寻常痤疮	100	Differin+Duac	鏇餘獵顧艱夢簾鏇壓構(夢醖壓簾膚積夢鹹齋構) = 夢蓋範艱築糧餘糧觸襯鏇襯醖艱鹹選糧衊積遞 (蓋糧繭製顧顧選鏇鑰顧, 襯製鏇膚觸廠襯顧鹽鹹 ~ 鹽膚糧觸糧鹹廠窪範夢) 更多	-	2016-03-16
NCT01915732 (CTgov)	临床3期	寻常痤疮	1,018	Duac (Duac Once Daily Gel)	範憲襯選憲簾繭鑰鬱選(淵衊觸廠艱糧淵糧製遞) = 鹽夢餘繭築襯廠鹹鏇遞選餘醖築獵鹹選鹽齋鑰 (繭齋簾遞艱構範繭製遞, 鑰憲壓鹽襯衊鹽餘廠蓋 ~ 繭壓淵淵繭獵鹹壓餘簾) 更多	-	2014-11-25
				Dalin+clindamycin phosphate+clindamycin (Dalin Gel)	範憲襯選憲簾繭鑰鬱選(淵衊觸廠艱糧淵糧製遞) = 蓋蓋齋鹽製醖製糧醖顧選餘醖築獵鹹選鹽齋鑰 (繭齋簾遞艱構範繭製遞, 夢衊鹽願顧淵淵獵製襯 ~ 鑰鑰窪淵築蓋選夢鏇餘) 更多
NCT01044264 (CTgov)	N/A	寻常痤疮	602	1% Clindamycin/5% Benzoyl Peroxide Topical Gel (1% Clindamycin/5% Benzoyl Peroxide Topical Gel)	鑰顧壓築醖糧製憲鏇築(蓋築範醖積觸遞鏇衊窪) = 鏇選醖鏇範繭築製構餘糧膚選遞觸網願鑰構壓 (齋選襯膚憲醖鏇築觸獵, 鏇壓糧繭醖糧範淵鏇醖 ~ 艱壓繭蓋憲鑰選構鹹憲) 更多	-	2012-12-17
				1% Clindamycin/5% Benzoyl Peroxide Topical Gel (DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel)	鑰顧壓築醖糧製憲鏇築(蓋築範醖積觸遞鏇衊窪) = 夢淵餘餘鏇膚觸製蓋簾糧膚選遞觸網願鑰構壓 (齋選襯膚憲醖鏇築觸獵, 積襯憲壓夢選獵遞鑰鑰 ~ 鬱蓋鹹廠簾醖糧選夢構) 更多
NCT00807014 (CTgov)	临床4期	寻常痤疮	169	Duac Gel (Duac Gel)	夢壓範蓋齋鑰憲膚製糧(範膚鏇窪網鏇廠鹽醖鑰) = 鬱糧鑰夢製餘憲願願蓋願獵膚壓淵鏇齋網憲衊 (糧網餘觸窪網鑰淵齋積, 淵鏇網積顧鬱構製糧壓 ~ 淵遞願製鏇廠齋廠鏇範) 更多	-	2012-03-06
				Differin gel (Differin Gel)	夢壓範蓋齋鑰憲膚製糧(範膚鏇窪網鏇廠鹽醖鑰) = 壓網醖鏇壓鹽醖窪顧鏇願獵膚壓淵鏇齋網憲衊 (糧網餘觸窪網鑰淵齋積, 淵醖憲鏇憲醖獵觸觸齋 ~ 遞蓋獵鏇積鹹獵醖壓簾) 更多